Brigatinib ALK inhibitors

brigatinib - AP26113



Trial Studied treatment Control Patients Size Study type Results NCT

Lung cancer (metastatic) - ALK inhibitors in ALK positive patients

ALTA-1L ongoing brigatinibcrizotinibNA NCT02737501



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons